Phase 1 to evaluate the safety and pharmacokinetics drug-drug interaction of YYC506-T and YYC506-A. Which is designed as two cohort, single-sequence, paralle, open label, multiple oral dosing.
To evaluate the safety and pharmacokinetics drug-drug interaction of YYC506-T and YYC506-A